Newton Fund - Accelerating cost-effective development of improved treatments for COPD and other respirtory diseases in China

牛顿基金 - 加速中国慢性阻塞性肺病和其他呼吸道疾病的改进治疗方法的成本效益开发

• 批准号: 102876
• 金额: $ 92.2万
• 依托单位: CRYSTEC LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2017
• 资助国家: 英国
• 起止时间: 2017 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=102876
• 关键词: Newton; Fund; Accelerating; cost; effective; Newton; Fund; Accelerating; cost; effective

This project focuses on cost effective health care provision for debilitating respiratory diseases, and especially chronic obstructive pulmonary disease (COPD). COPD currently affects 1 in 12 of the Chinese population over 40. Frequently patients respond poorly to current treatment due to drug resistance. Our innovative approach will overcome this issue with an inexpensive, simple, efficacious, dry powder inhaler (DPI) device containing a novel combination of two existing drugs. Innovative supercritical fluid (SCF) technology uniquely provides the ability to prepare the high specification drug powders required. Essential knowledge requirements for the project will be met by bridging leading centres - Crystepharma and Imperial College in the UK with SIMM and Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. in China. Outcomes will include ‘first in man’ studies for the new DPI, and creating a preclinical testing centre and SCF manufacturing facilities in China. In addition to the COPD product, a range of improved drug/device patient inhaled products will be developed aimed to treat cost effectively other widespread respiratory disease challenges in China.

该项目着重于具有成本效益的医疗保健，以使呼吸道疾病，尤其是慢性阻塞性肺疾病（COPD）。 COPD目前会影响40多个中国人口中的12人中的1人。由于耐药性，患者经常对当前治疗的反应较差。我们的创新方法将通过一种廉价，简单，高效，干粉吸入器（DPI）设备来克服这个问题，该设备含有两种现有药物的新型组合。创新的超临界流体（SCF）技术独特地提供了准备所需的高特定药物粉末的能力。该项目的基本知识要求将通过桥接领先的中心 - 在英国与西姆和上海富丹·兹海安格·兹海安（Simm and Shanghai fudan-Zhangjiang Bio-Pharmaceutical Co.成果将包括新DPI的“人类研究”，并在中国创建临床前测试中心和SCF制造设施。除COPD产品外，还将开发一系列改进的药物/装置患者遗传产品，旨在有效地治疗中国其他宽大呼吸道疾病挑战。